Aelis Farma first established its research and development on an exclusive collaboration with the Neurocentre Magendie in Bordeaux, one of the most respected and highly innovative Neuroscience Research centers in Europe with extensive experience in the CB1 receptor.
Aelis Farma also collaborate with a panel of other prestigious research organization and laboratories which provide the company with an outstanding expertise in the field of signaling specific drugs for the CB1 receptor and other similar GPCRs:
In collaboration with Columbia University, Aelis Farma has been granted a 3.3 MUSD financing from NIDA (National Institute on Drug Abuse) in order to finance the first clinical studies for its lead compound AEF0117 in the treatment of cannabis abuse. To comply with specific NIH requirements, Aelis Farma has set up a FCOI (Financial Conflicts of Interest) policy:fcoi-policy-aelis-farma
Inserm Transfert Initiative
BPI France Participations
Aquitaine Création Investissement